GnRH Analog Treatment before Hysteroscopic Resection of Submucous Myomas: A Randomized Study

Muzii, Ludovico; Boni, Terenzio; Bellati, Filippo; Marana, Riccardo; Zullo, Marzio Angelo; Angioli, Roberto; P, Benedetti Panici

doi:10.1016/j.jmig.2008.09.252

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GnRHas are associated with a greater decrease in fibroid and uterine volume compared to SPRMs. 9,29 When compared to no pretreatment, use of a GnRHa is associated with decreased fluid absorption at hysteroscopic myomectomy, 30,31 and decreased blood loss and transfusions at laparotomic/laparoscopic myomectomy 29,32 (Level I, A). The primary advantage of UPA over GnRHas is the rapid control of uterine bleeding (5-7 days with 10-and 5-mg UPA doses, respectively, vs 21 days for leuprolide, P < .01).…”

Section: The Pastmentioning

confidence: 99%

The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids

Singh

Belland

Leyland

et al. 2018

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Uterine fibroids are common in women of reproductive age and can have a significant impact on quality of life and fertility. Although a number of international obstetrics/gynecology societies have issued evidence-based clinical practice guidelines for the management of symptomatic uterine fibroids, many of these guidelines do not yet reflect the most recent clinical evidence and approved indication for one of the key medical management options: the selective progesterone receptor modulator class. This article aims to share the clinical experience gained with selective progesterone receptor modulators in Europe and Canada by reviewing the historical development of selective progesterone receptor modulators, current best practices for selective progesterone receptor modulator use based on available data, and potential future uses for selective progesterone receptor modulators in uterine fibroids and other gynecologic conditions.

show abstract